-+ 0.00%
-+ 0.00%
-+ 0.00%

Biotech (688177.SH): Usinumab injection received positive opinions from the European Medicines Agency's Human Medicines Committee

Zhitongcaijing·06/20/2025 08:17:02
Listen to the news

Zhitong Finance App News, Biotech (688177.SH) announced that the company recently received a notice from the European Medicines Agency (“EMA”), and Usymro® (BAT2206, usinumab injection) received positive opinions from the EMA Human Drugs Commission (“CHMP”). The CHMP recommended that the European Commission (EC) approve the marketing of Usymro ® for the treatment of adults and children: moderate to severe plaque psoriasis (PsO), active psoriatic arthritis (pSA), and moderate to severe active Crohn's disease (CD).